Effect of spironolactone and minoxidil solution in treatment of androgenic alopecia

Efficacy and safety of minoxidil 5% with or without spironolactone 2% in treating patients with androgenic alopecia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181005041243N2

Enrollment

Registered

2022-10-12

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia. Androgenic alopecia

Interventions

Intervention 1: Intervention group 1: minoxidil 5% solution/ The solution would be applied on the head twice a day (morning and night) for 6 months. This solution will be manufactured by the pharmacy

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Aged 18-60 Clinical diagnosis of androgenic alopecia with a dermatologist Have not received any drug for alopecia in the past 12 months

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding during the intervention history of internal diseases, including endocrine diseases causing alopecia alteration in diet and lifestyle during the study polycystic ovary syndrome The disease caused by another reason than androgenic alopecia Consuming any systemic or topical drugs which caused hair loss or hair regrowth Have a history of hair transplantation History of skin diseases which cause hair loss like cutaneous cancers, infection, psoriasis photosensitivity

Design outcomes

Primary

Measure	Time frame
Hair regrrowth score. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Hair regrowth score based on the observations of two dermatologists assessing the before and after photographs.	—

Secondary

Measure	Time frame
Patients' satisfaction with androgenic alopecia recovery. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Visual Analogue Scale.;Hair regrowth score based on Fotofinder device. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Hair density (hairs/cm2) and Hair diameter (hairs/cm2).	—

Measure

Time frame

Patients' satisfaction with androgenic alopecia recovery. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Visual Analogue Scale.;Hair regrowth score based on Fotofinder device. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Hair density (hairs/cm2) and Hair diameter (hairs/cm2).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNika Kianfar

Tehran University of Medical Sciences

nika_kianfar@yahoo.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026